Unknown

Dataset Information

0

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19.

ABSTRACT:

SUBMITTER: Della-Torre E 

PROVIDER: S-EPMC8555969 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19.

Della-Torre Emanuel E   Criscuolo Elena E   Lanzillotta Marco M   Locatelli Massimo M   Clementi Nicola N   Mancini Nicasio N   Dagna Lorenzo L  

The Lancet. Rheumatology 20211029 12

Similar Datasets

Unknown SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19
| S-EPMC8135631 | biostudies-literature
Unknown SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
| S-EPMC9205158 | biostudies-literature
Unknown SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
| S-EPMC8411904 | biostudies-literature
Unknown Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation.
| S-EPMC7781345 | biostudies-literature
Unknown SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
| S-EPMC10058662 | biostudies-literature
Unknown Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19.
| S-EPMC8624589 | biostudies-literature
Unknown Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
| S-EPMC8489294 | biostudies-literature
Unknown Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.
| S-EPMC7264175 | biostudies-literature
Unknown Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.
| S-EPMC7279746 | biostudies-literature
Unknown Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies.
| S-EPMC12148588 | biostudies-literature